Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
News headline image
Here's Why Sage Therapeutics Stock Is Sliding Today ↗
Long-awaited clinical trial results weren't as successful as hoped. 
Via The Motley Fool
News headline image
Mid-Day Market Update: Crude Oil Rises 1%; Sage Therapeutics Shares Slide ↗
Midway through trading Tuesday, the Dow traded down 0.45% to 34,238.18 while the NASDAQ fell 0.53% to 14,099.27. The S&P also fell, dropping 0.25% to 4,244.45. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
34 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers HMG/Courtland Properties, Inc. (NYSE: HMG) shares surged 133% to $27.80. Alfi, Inc. (NASDAQ: ALF) shares jumped 82.1% to $6.21 after the company inked an agreement with... 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug ↗
Biogen Inc. (NASDAQ: BIIB) stock is seeing muted sentiment Tuesday as it emerges from the euphoria over Aduhelm approval, with the most recent trigger being lukewarm data for a... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Drop 1.3% In May ↗
Following the market opening Tuesday, the Dow traded down 0.34% to 34,275.92 while the NASDAQ fell 0.09% to 14,161.73. The S&P also fell, dropping 0.10% to 4,250.89. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
Sage Stock Tumbles As Analysts Question Its 'Positive' Test In Depression ↗
The results showed an improvement over placebo. But that improvement waned over time. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Clearside Biomedical (NASDAQ:CLSD) stock increased by 50.99% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
News headline image
Why Sage Therapeutics (SAGE) Stock Is Falling Despite Meeting Primary Endpoint In Major Depressive Disorder Trial With Zuranolone ↗
Looking to make a comeback after a big Phase 3 flop, Sage Therapeutics Inc (NASDAQ: SAGE) revealed data from another Phase 3 evaluating zuranolone in patients with... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
News headline image
Sage Therapeutics to Host Conference Call
From Sage Therapeutics
Via Business Wire
News headline image
Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms ↗
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/... 
Via Benzinga
News headline image
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch ↗
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm. Notwithstanding the still-raging debate over the decision, an... 
Via Benzinga
News headline image
3 Biotech Stocks With Huge Catalysts in June ↗
Binary events expected this month could have enormous implications for these drugmakers and their shareholders. 
Via The Motley Fool
News headline image
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks ↗
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. 
Via Investor's Business Daily
News headline image
Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day
From Sage Therapeutics
Via Business Wire
Betting Big On What Could Be The Next Great Biotech Boom
Via FinancialNewsMedia
News headline image
Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth
From Sage Therapeutics
Via Business Wire
News headline image
Sage Therapeutics Inc (SAGE) Q1 2021 Earnings Call Transcript ↗
SAGE earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics to Present at Upcoming May Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out ↗
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last... 
Via Benzinga
News headline image
Earnings Scheduled For May 4, 2021 ↗
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
Via Benzinga
News headline image
Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug ↗
Sage Therapeutics unveiled promising results for its essential tremors treatment, but Sage stock tripped on worse-than-expected side effects. 
Via Investor's Business Daily
News headline image
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Biotech Stocks Could Use A Win — Will The First Quarter Offer That? ↗
Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. 
Via Investor's Business Daily
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.